These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
619 related articles for article (PubMed ID: 21126633)
1. Lenalidomide: an update on evidence from clinical trials. Dimopoulos MA; Terpos E Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633 [TBL] [Abstract][Full Text] [Related]
2. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100 [TBL] [Abstract][Full Text] [Related]
3. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. Morgan G Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634 [TBL] [Abstract][Full Text] [Related]
4. Lenalidomide in the treatment of multiple myeloma: a review. Armoiry X; Aulagner G; Facon T J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408 [TBL] [Abstract][Full Text] [Related]
5. Lenalidomide mode of action: linking bench and clinical findings. Davies F; Baz R Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632 [TBL] [Abstract][Full Text] [Related]
6. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; FoĆ R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD; N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762 [TBL] [Abstract][Full Text] [Related]
7. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112 [TBL] [Abstract][Full Text] [Related]
8. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide. Mariz JM; Esteves GV Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806 [TBL] [Abstract][Full Text] [Related]
10. Lenalidomide and its role in the management of multiple myeloma. Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. Bringhen S; Gay F; Pautasso C; Cerrato C; Boccadoro M; Palumbo A Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1209-22. PubMed ID: 22862790 [TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Palumbo A; Dimopoulos M; San Miguel J; Harousseau JL; Attal M; Hussein M; Knop S; Ludwig H; von Lilienfeld-Toal M; Sonneveld P Blood Rev; 2009 Mar; 23(2):87-93. PubMed ID: 18774632 [TBL] [Abstract][Full Text] [Related]
13. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031 [TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. Hazarika M; Rock E; Williams G; Dagher R; Sridhara R; Booth B; Farrell A; Justice R; Pazdur R Oncologist; 2008 Oct; 13(10):1120-7. PubMed ID: 18922829 [TBL] [Abstract][Full Text] [Related]
16. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Schey SA; Morgan GJ; Ramasamy K; Hazel B; Ladon D; Corderoy S; Jenner M; Phekoo K; Boyd K; Davies FE Br J Haematol; 2010 Aug; 150(3):326-33. PubMed ID: 20553268 [TBL] [Abstract][Full Text] [Related]
17. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma. Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702 [TBL] [Abstract][Full Text] [Related]
18. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. San-Miguel JF; Dimopoulos MA; Stadtmauer EA; Rajkumar SV; Siegel D; Bravo ML; Olesnyckyj M; Knight RD; Zeldis JB; Harousseau JL; Weber DM Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):38-43. PubMed ID: 21273172 [TBL] [Abstract][Full Text] [Related]
19. Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. Larocca A; Cavallo F; Mina R; Boccadoro M; Palumbo A Future Oncol; 2012 Oct; 8(10):1223-38. PubMed ID: 23130924 [TBL] [Abstract][Full Text] [Related]
20. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]